Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: Moclobemide and selegiline

被引:15
作者
Dingemanse, J
Kneer, J
Wallnofer, A
Kettler, R
Zurcher, G
Koulu, M
Korn, A
机构
[1] F HOFFMANN LA ROCHE & CO LTD,DEPT PRECLIN RES,CH-4002 BASEL,SWITZERLAND
[2] UNIV TURKU,DEPT PHARMACOL,TURKU,FINLAND
[3] UNIV HOSP VIENNA,DEPT ENDOCRINOL,VIENNA,AUSTRIA
关键词
moclobemide; selegiline; pharmacokinetics; pharmacodynamics; interactions; catecholamines; serotonin; monoamine oxidase inhibitors;
D O I
10.1097/00002826-199619050-00003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The objectives of this study were to assess potential pharmacokinetic and pharmacodynamic interactions between moclobemide and selegiline, Two groups of 12 healthy male and female subjects were treated with 200 mg moclobemide or 5 mg selegiline b.i.d. for 16 days. On study day 8, the alternative active drug or placebo was added to the respective treatments, Concentration-time profiles of moclobemide and two of its main metabolites and 3,4-dihydroxyphenylglycol (DHPG, a norepinephrine metabolite), 5-hydroxyindoleacetic acid (HIAA, a serotonin metabolite), and 3,4-dihydroxyphenylacetic acid (DOPAC, a dopamine metabolite) in plasma as well as MAO-B activity and serotonin concentration in platelets were determined at steady state during monotreatment and combined treatment, The pharmacokinetic parameters of moclobemide and its metabolites changed on multiple dosing but were not influenced to a relevant extent by concomitant administration of selegiline. The measured pharmacodynamic parameters, expressed as the maximum effect on a study day and the area under the effect-time curve, characterized the drugs' influence on peripheral neurotransmitter metabolism, The most reliable variables to assess inhibition of MAO-A and -B in humans proved to be DHPG in plasma and serotonin in platelets and MAO-B activity in platelets, respectively. Several variables (DHPG, platelet serotonin) suggested that selegiline has some MAO-A inhibitory activity, This became particularly apparent upon addition of selegiline to moclobemide treatment; i.e., the effects of combined moclobemide and selegiline treatment were statistically greater than those of moclobemide monotreatment. Moclobemide alone exerted a slight inhibition of platelet MAO-B activity, The reported pharmacodynamic interactions are not considered to be clinically relevant. However, due to the previously found supraadditive tyramine potentiation upon simultaneous treatment, moclobemide and selegiline should only be combined when applying dietary restrictions with respect to tyramine.
引用
收藏
页码:399 / 414
页数:16
相关论文
共 62 条
[1]   INTERACTIONS OF MOCLOBEMIDE WITH CONCOMITANTLY ADMINISTERED MEDICATION - EVIDENCE FROM PHARMACOLOGICAL AND CLINICAL-STUDIES [J].
AMREIN, R ;
GUNTERT, TW ;
DINGEMANSE, J ;
LORSCHEID, T ;
STABL, M ;
SCHMIDBURGK, W .
PSYCHOPHARMACOLOGY, 1992, 106 :S24-S31
[2]  
[Anonymous], REV CONT PHARMACOTHE
[3]   FLUOXETINE, FLUVOXAMINE AND EXTRAPYRAMIDAL TRACT DISORDERS [J].
BALDWIN, D ;
FINEBERG, N ;
MONTGOMERY, S .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1991, 6 (01) :51-58
[4]   MEASUREMENT OF HUMAN CEREBRAL MONOAMINE-OXIDASE TYPE-B (MAO-B) ACTIVITY WITH POSITRON EMISSION TOMOGRAPHY (PET) - A DOSE RANGING STUDY WITH THE REVERSIBLE INHIBITOR RO-19-6327 [J].
BENCH, CJ ;
PRICE, GW ;
LAMMERTSMA, AA ;
CREMER, JC ;
LUTHRA, SK ;
TURTON, D ;
DOLAN, RJ ;
KETTLER, R ;
DINGEMANSE, J ;
DAPRADA, M ;
BIZIERE, K ;
MCCLELLAND, GR ;
JAMIESON, VL ;
WOOD, ND ;
FRACKOWIAK, RSJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (02) :169-173
[5]   COMPARISON OF THE MONOAMINE-OXIDASE INHIBITING PROPERTIES OF 2 REVERSIBLE AND SELECTIVE MONOAMINE OXIDASE-A INHIBITORS MOCLOBEMIDE AND TOLOXATONE, AND ASSESSMENT OF THEIR EFFECT ON PSYCHOMETRIC PERFORMANCE IN HEALTHY-SUBJECTS [J].
BERLIN, I ;
ZIMMER, R ;
THIEDE, HM ;
PAYAN, C ;
HERGUETA, T ;
ROBIN, L ;
PUECH, AJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (06) :805-816
[6]  
BLACKWELL B, 1991, J CLIN PSYCHOPHARM, V11, P55
[7]  
BONDIOLOTTI G P, 1992, Experientia (Basel), V48, pA7
[8]  
Brown M. J., 1984, MONOAMINE OXIDASE DI, P559
[9]   PLASMA 5-HYDROXYINDOLEACETIC ACID AS AN INDICATOR OF MONOAMINE OXIDASE-A INHIBITION IN RAT-BRAIN AND PERIPHERAL-TISSUES [J].
CELADA, P ;
ARTIGAS, F .
JOURNAL OF NEUROCHEMISTRY, 1993, 61 (06) :2191-2198
[10]  
CELADA P, 1992, J CLIN PSYCHOPHARM, V12, P309